Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b/2a Safety and Tolerability Study of ZEN003694 in Combination With Enzalutamide in Patients With Metastatic Castration-Resistant Prostate Cancer

NCT02711956 is registered in ClinicalTrials.gov with Zenith Epigenetics as lead sponsor.

NCT NCT02711956
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02711956 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b/2a Safety and Tolerability Study of ZEN003694 in Combination With Enzalutamide in Patients With Metastatic Castration-Resistant Prostate Cancer
Lead sponsor
Zenith Epigenetics
Phase
Phase 1/2
Overall status
Completed
Start date
December 31, 2016
Completion date
November 30, 2019
Enrollment
75 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic castration-resistant prostate cancer